Clinical Trials

AACR 2026 is Still Moving Biotech Stocks: What Investors Should Watch

AACR 2026 is already moving biotech stocks across ADCs, radiopharmaceuticals, and cell therapies. Here is what investors should watch next.

How to Tell Whether Clinical News Is Progress or Noise

Learn how to tell whether biotech clinical news is real progress or just noise so you can focus on meaningful catalyst updates.

What Is a Companion Diagnostic?

Learn what a companion diagnostic is, why it matters for precision medicine, and how it affects biotech development and commercialization.

What Is Combination Therapy?

Learn what combination therapy means in biotech, why it matters in oncology and chronic disease, and how it shapes trial and market strategy.

What Is Line of Therapy?

Learn what line of therapy means in biotech and oncology, and why first-line, second-line, and later-line treatment matter for investors.

What Is an Indication in Biotech?

Learn what an indication is in biotech, why it matters for approval and commercialization, and how indication news affects stock valuations.

What Is a Biomarker?

Learn what a biomarker is in biotech, how biomarkers are used in trials, and why biomarker news matters for drug development and investing.

What Is a Surrogate Endpoint?

Learn what a surrogate endpoint is, why it matters in biotech, and how it supports faster regulatory decisions and accelerated approval.

What Is a Secondary Endpoint?

Learn what a secondary endpoint is, how it supports clinical trial interpretation, and why it matters in biotech data releases.

What Is a Primary Endpoint?

Learn what a primary endpoint is, why it matters most in clinical trials, and how investors use it to judge biotech readouts.

What Is a Clinical Trial Endpoint?

Learn what a clinical trial endpoint is, why endpoints matter in biotech, and how they shape the interpretation of trial results and news.

Drug Development in Biotech: From Discovery to Approval

Learn the full biotech drug development process from discovery to approval, including preclinical work, clinical phases, filing, review, and launch.

What Is Interim Data? How It Differs From Final Trial Results

Learn what interim data means in biotech, why companies release it, and how it differs from final clinical trial results and top-line readouts.

What Is Top-Line Data? Why It Shows Up So Often in Biotech Headlines

Learn what top-line data means in biotech, why companies announce it first, and why investors pay close attention to headline clinical results.

What Is Data Lock? Why It Matters Before a Clinical Readout

Learn what data lock means in biotech, why it matters before a clinical readout, and how it affects timing, confidence, and news flow.

Why Clinical Trial Dates Change So Often, and How News Systems Should Handle It

Learn why clinical trial timelines change, what causes delays in biotech, and how news systems can track shifting readout and enrollment dates.

What Is a Phase 3 Data Release? Why It Usually Has the Biggest Impact

Learn what a Phase 3 data release is, why late-stage readouts matter most, and how investors use Phase 3 results to judge approval and launch potential.

What Is a Phase 2 Data Release? How It Differs From Phase 1

Learn what a Phase 2 data release is, why it matters more than Phase 1, and how investors use mid-stage biotech data to judge momentum.

What Is a Phase 1 Data Release? Why Early-Stage Readouts Matter

Learn what a Phase 1 data release is, what investors look for in early biotech data, and why first-in-human readouts can shape market sentiment.

What Is a Clinical Trial Readout? Why It Often Shapes Market Sentiment

Learn what a clinical trial readout is, what investors look for in biotech data releases, and why readouts often move stocks and market sentiment.